LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller received a direct employee stock option award covering 200,000 shares of common stock on October 9, 2026. The options have an exercise price of $37.22 per share and expire October 8, 2036. Vesting is subject to Miller’s continuous service through each vesting date.
LB Pharmaceuticals Inc. granted Chief Medical Officer Susan Gani Kozauer 200,000 employee stock options on October 9, 2026, with an exercise price of $37.22 per share and an expiration date of October 8, 2036. One fourth of the option shares vest on September 14, 2027; the remainder vest monthly over the following three years beginning September 30, 2027, subject to Kozauer’s continuous service through each vesting date.
JPMorgan Chase & Co. reported beneficial ownership of 1,401,790 shares of LB Pharmaceuticals Inc. common stock, equal to 4.3% of the class as of September 30, 2026. The report identifies ownership of 5% or less of the class.
LB Pharmaceuticals Inc. is terminating the effectiveness of its Form S-1 registration and removing securities that remain unsold. The S-1 had registered the offer and resale of up to an aggregate of 4,778,491 common shares by selling stockholders. Offers and sales under the S-1 terminate upon effectiveness of the Form S-3ASR, which registers unsold or unissued shares covered by the S-1.
LB Pharmaceuticals Inc. has a shelf registration that permits the company and selling securityholders to offer common and preferred stock, debt securities, warrants and units, with specific terms to be set in prospectus supplements. It also includes a selling-stockholder prospectus for resales of unsold shares previously registered on a Form S-1 and additional common shares. Unless a supplement provides otherwise, the company receives no proceeds from selling-securityholder sales. For company sales, net proceeds are currently intended for general corporate purposes, including research and development, selling, general and administrative expenses, and capital expenditures.
LB Pharmaceuticals Inc. (LBRX) lists Susan Gani Kozauer as Chief Medical Officer in an initial ownership report.
LB Pharmaceuticals Inc (LBRX) filed a prospectus supplement to its Form S-1 registration statement to incorporate a Current Report on Form 8-K announcing the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. The supplement does not change the securities previously registered but updates disclosure for investors.
Under her employment agreement, Dr. Kozauer receives an initial annual base salary of $515,000, a target annual bonus equal to 40% of base salary, and a one-time cash sign-on bonus of $150,000, subject to a two-year service-based earn-out and potential repayment of unearned portions. Subject to board approval, she will receive an inducement stock option to purchase 200,000 shares, vesting over four years, granted in accordance with Nasdaq Listing Rule 5635(c)(4). The agreement provides at-will employment with defined severance and change-of-control protections, including salary continuation, COBRA premium reimbursements, and potential accelerated vesting of equity awards upon qualifying termination events.
LB Pharmaceuticals Inc (LBRX) appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026, under an at-will employment agreement that includes cash compensation, equity incentives, and change-of-control protections.
Dr. Kozauer will receive an initial annual base salary of $515,000, a target annual bonus equal to 40% of base salary, and a one-time cash sign-on bonus of $150,000, of which she effectively earns 50% on each of the first two anniversaries of her start date. Subject to board approval, she will also receive an option to purchase 200,000 shares of common stock, vesting over four years, granted as an inducement award under Nasdaq Listing Rule 5635(c)(4). If she is terminated without cause or resigns for good reason, she is entitled to severance benefits, including up to nine to twelve months of base salary and COBRA reimbursement, with enhanced cash and full equity acceleration if this occurs around a change of control.
LB PHARMACEUTICALS INC (ticker LBRX) reports that its Chief Financial Officer, Joseph M. Miller, has filed an initial statement of beneficial ownership on Form 3. The filing shows no reportable equity holdings or transactions for him at this time.